September 5, 2024 06:33 AM EDTUpdated 07:14 AM
People
R&D

IN8bio paus­es glioblas­toma pro­gram, halves work­force as it pri­or­i­tizes leukemia as­set

Ayisha Sharma

News Reporter

IN8bio is putting its brain tu­mor de­vel­op­ment pro­gram on the back burn­er and ax­ing al­most half of its em­ploy­ees in an ef­fort to cut costs …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

In sur­prise, study sug­gests Covid mR­NA vac­cines may boost can­cer im­munother­a­py ef­fi­ca­cy

Ex-Kite lead­ers step in at Kyver­na as CEO ex­its af­ter land­ing year's sec­ond-biggest IPO

Pfiz­er tees up Phase 3 test in weight man­age­ment — but in an un­ex­pect­ed area

BioN­Tech rolls out Phase 2 lung can­cer da­ta as VEGF bis­pecifics take cen­ter stage

Im­mat­ics los­es Bris­tol My­er­s' sup­port on Phase 1 bis­pe­cif­ic T cell en­gager

sponsored

Break­ing down si­los with a new quan­ti­ta­tive ap­proach to drug de­vel­op­ment

A service from the Financial Times